Letters by company
PharmChem Inc
3 letters discussing PCHM. Everything written about it on this site is on its ticker page.
- Cedar Creek Partners Cedar Creek Partners 2025 Third Quarter Results Cedar Creek Partners sold PharmChem following its buyout and exited Citizens Bancshares, redirecting much of the proceeds into PHI Group and other undervalued community banks. The portfolio increased its expert-market exposure, with substantial positions in Propel Media, PHI Group and First IC, while Solitron’s order backlog and ENDI’s asset-management growth supported the investment cases. Q3 ‘25 CZBS $116MENDI $129MPHIG $754M
- Cedar Creek Partners Cedar Creek Partners 2025 Second Quarter Results Cedar Creek Partners increased its CBE LLC investment, taking cash levels lower, and emphasized undervalued microcap and expert-market holdings. The fund argued that Propel Media's growing DeepIntent borrowing base signals revenue growth, while Solitron, PharmChem and ENDI offer catalysts through defense orders, a sale process and CrossingBridge asset growth. 2025 Second Quarter ENDI $129MPHIG $754MSODI $78M
- Cedar Creek Partners Cedar Creek Partners 2025 First Quarter Results Cedar Creek Partners added to Western Capital Resources after its tender offer and to Evercel on the view that its shares retain rights to ZAGG liquidation proceeds. The fund built a Skyline Bankshares position, maintained a large expert-market allocation led by Propel Media and First IC, and argues that Solitron's backlog, ENDI's asset growth and PharmChem's strategic review support value. 2025 First Quarter CZBS $116MENDI $129MSLBK $159M
